AstraZeneca and Amgen tracked psoriasis patients taking brodalumab, ustekinumab (Stelara), or placebo, and the results showed brodalumab produced the greatest results in clearing skin.
Meghan Ross, Associate Editor
Advertisement
Articles by Meghan Ross, Associate Editor
A pharmacist who pleaded guilty to drug trafficking and money laundering charges in 2012 is trying his hardest to hold onto his pharmacy license, according to the Tampa Bay Times.
Gilead Sciences Inc. has reported positive results from its phase 2 and phase 3 studies on ledipasvir 90 mg/sofosbuvir 400 mg in patients with chronic hepatitis C virus.
In a recent phase 2b study, patients with asthma reported reduced exacerbations and improved lung function after receiving dupilumab, an investigational therapy from Sanofi-Aventis and Regeneron Pharmaceuticals Inc.
A study exploring Merck's experimental hepatitis C virus treatment has provided proof-of-concept for a 6- to 8-week course of triple therapy.
The FDA is taking a look at Amgen's Biologics License Application for evolocumab.
Treating patients with type 2 diabetes mellitus just got a little easier.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
2
Evolving Mortality Trends in Heart Failure and Vascular Disease: The Critical Role of Pharmacists in Addressing Cardiovascular Risk
3
Sotatercept Demonstrates Significant Reduction in Morbidity and Mortality Across Broader PAH Risk Groups
4
SGLT2 Inhibitors Linked to Lower Atrial Fibrillation Risk, Recurrence
5
